Trials / Unknown
UnknownNCT04749485
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
A Single-armed Open-labeled Phase II Study of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) for the Treatment of Patients With Locally Advanced or Metastatic Melanoma Who Have Failed the Standard Treatments.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Taizhou Hanzhong biomedical co. LTD · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the efficacy and safety of HX008 in patients with locally advanced or metastatic melanoma who have failed the standard treatments will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HX008 | Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal. |
Timeline
- Start date
- 2018-11-08
- Primary completion
- 2020-08-19
- Completion
- 2021-11-08
- First posted
- 2021-02-11
- Last updated
- 2021-02-11
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04749485. Inclusion in this directory is not an endorsement.